Document |
Document Title |
WO/2024/102421A2 |
The invention features compounds containing an aziridine moiety and methods of synthesizing the same. The compounds may be bound to a monovalent organic moiety and may be used to bind to a target (e.g., a target protein), for example, by...
|
WO/2024/066548A1 |
The present invention provides a β-elemene derivative containing the photoaffinity group diazirine, a preparation method therefor, and use thereof as a photoaffinity molecular probe. The present invention provides a compound of a struct...
|
WO/2023/213713A1 |
Ethanolamines, polyethylenimine and ammonia having a low molar share of deuterium, a process for making ethanolamines, polyethylenimine and ammonia based on non- fossil energy, the use of the molar share of deuterium in hydrogen and down...
|
WO/2023/206874A1 |
A sacubitril intermediate, a preparation method therefor, and use thereof. A key intermediate N-Boc amino alcohol represented by formula (10) or formula (10-a) can be efficiently prepared. The intermediate can be used to prepare a neutra...
|
WO/2023/182754A1 |
The present invention relates to an organic compound that can enhance the light efficiency of light extracted to the outside of an organic light-emitting element due to having a low refractive index, and thus can be effectively utilized ...
|
WO/2023/168827A1 |
The present invention relates to the technical field of chemical intermediates. Disclosed is a synthesis method for a paxlovid intermediate, comprising the following steps: reacting 3,3-dimethyl-4-oxobutyrate with S-substituted sulfinami...
|
WO/2023/135532A1 |
The invention concerns a compound of formula (I) or pharmaceutically acceptable salts or hydrates thereof: (I) wherein R represents a 6-membered aryl or heteroaryl group or a 5-membered heteroaryl group, optionally substituted with at le...
|
WO/2023/036878A1 |
The present invention refers to novel UV-light cleavable drug conjugates comprising a diazirine linker.
|
WO/2023/028022A1 |
A method of synthesizing a pharmacological compound substance by attaching a psychoactive base substance to an amino acid and creating a prodrug with modified pharmacological behavior. A prodrug made by the method. A pharmaceutical compo...
|
WO/2023/008644A1 |
The present invention relates to an organic compound and an organic light-emitting device comprising same, the organic compound being employed in an optical efficiency improvement layer, which is provided in an organic light-emitting dev...
|
WO/2022/231580A1 |
A pharmaceutical composition, including a compound l-(3-(3-N,N- dimethylaminocarbonyl)phenoxyl-4-mtrophenyl)-l-ethyl-N,N'- bis(ethylene)phosphoramidate and at least one therapeutic agent including a chemotherapeutic agent or biological a...
|
WO/2022/187932A1 |
A family of novel diazirine-based molecules is disclosed, as well as methods of manufacture and uses thereof. These compounds allow non-functionalized polymers, such as polyolefins, to crosslink via C–H insertion. Such a C–H insertio...
|
WO/2022/160466A1 |
A 2-cyanoacrylate compound and use thereof for preventing and treating fungal diseases of crops, belonging to the field of fungicides. The 2-cyanoacrylate compound has good fungicidal activity, particularly has good fungicidal activity a...
|
WO/2021/245705A1 |
The present invention relates to azirine containing compounds useful as anti-angiogenesis agents and preparation thereof. Particularly the present invention relates to azirine containing compounds of formula I, Formula I wherein R1, R2 a...
|
WO/2021/161887A1 |
[Problem] To provide a novel compound which has high absorption selectivity for the long-wavelength ultraviolet to near ultraviolet region close to a wavelength of 400 nm, exhibits high weathering resistance, and has a merocyanine skelet...
|
WO/2021/148556A1 |
The invention relates to particles comprising a particular (aziridinyl hydroxy)-functional organic component. The invention further relates to mixtures comprising said particles. The invention further relates to aqueous dispersions compr...
|
WO/2021/148561A1 |
The present application relates to aziridine functional compounds with reduced genotoxicity and good crosslinking efficiency, for use in the preparation of, for example, coatings.
|
WO/2021/148558A1 |
The invention relates to particular (aziridinyl hydroxy)-functional organic component. The invention further relates to liquid compositions comprising said (aziridinyl hydroxy)-functional organic component. The invention further relates ...
|
WO/2021/141507A1 |
The invention relates to a new group of aromatic sulphonamides derivatives of formula (I) and their synthesis and use for modulation of the activity of protein disulfide isomerase (PDI). More particularly, the invention provides small mo...
|
WO/2021/141508A1 |
Present patent application disclose family of aromatic sulphonamides derivatives, their method of synthesis, and use as medicament, in particular for the treatment of infection with influenza A virus.
|
WO/2021/141506A1 |
The invention relates to a new group of aromatic sulphonamides derivatives of formula (I) and their synthesis and use for modulation of the activity of protein disulfide isomerase (PDI). More particularly, the invention provides small mo...
|
WO/2021/102568A1 |
This disclosure relates generally to cannabinoid derivatives having the structural formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives. In some embodiments, R1 is - CH2CH=C(CH3)2, R2...
|
WO/2021/007661A1 |
The current application relates to cannabinoid derivatives of formula (I) and pharmaceutical compositions comprising the same. The cannabinoid derivative can be used for the treatment of diseases associated with cannabinoid receptor such...
|
WO/2020/180624A1 |
Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein A, X1, X2, Q, R1, R2 and n are as defined herein. Such compounds function ...
|
WO/2020/170022A1 |
This invention relates to the novel potentially therapeutic compounds that contain l-acyl derivatives of aziridine-2-carboxamide and their analogues with the anticancer and/or antiproliferative, and/or antimetastatic properties and/or th...
|
WO/2020/146568A1 |
A method for the synthesis of diazabicyclo[6.2.0]decane compounds is provided. The synthesis proceeds by stereoselective synthesis of a chiral lactone followed by azetidine formation via a series of chemoselective reactions. Bicyclizatio...
|
WO/2020/023881A1 |
The invention provides a method for inactivation or reduction of pathogens, microorganisms or parasites in a sample, media, composition, utility, device, surface or organism by treatment with an alkylating compound of Structure I, follow...
|
WO/2019/091179A1 |
Disclosed is a method for preparing florfenicol intermediate V, which belongs to the technical field of the preparation of veterinary medicines. The method comprises an addition reaction, a ring-closing reaction, a hydrolysis reaction an...
|
WO/2019/075574A1 |
The present application relates to conduritol aziridines of Formula (I), and uses thereof, for example, of 18F-labelled derivatives thereof in positron-emission tomography (PET) imaging of β-glucocerebrosidase activity.
|
WO/2019/069297A2 |
Activity-based probes that can be used to selectively identify and characterize enzymes that are involved in different phases of xenobiotic metabolism in a host and its microbiota population(s) are described. The activity-based probes de...
|
WO/2018/231795A1 |
Compounds, pharmaceutically acceptable salts, and pharmaceutical compositions thereof are disclosed that are useful for inhibition of the biological activity of CCL2, as well as methods of treatment for diseases involving the biological ...
|
WO/2018/175190A1 |
Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
|
WO/2018/175188A1 |
Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of sigma- 2 receptor activity.
|
WO/2018/084625A1 |
The present invention relates to a novel method for preparing (S)-N1-(2-aminoethyl)-3-(4-alkoxyphenyl)propane-1,2-diamine trihydrochloride.
|
WO/2018/067842A1 |
The invention relates to new amino dimeric naphthoquinone compounds with antileukemic activity. Compounds of the invention demonstrated increased aqueous solubility compared to previously available dimeric naphthoquinones and potent nano...
|
WO/2018/004066A1 |
The present invention relates to an aryl ethane derivative, for inhibiting an estrogen-related receptor gamma (ERRγ) activity, a prodrug of same, a solvate of same, a stereoisomer of same or pharmaceutically acceptable salts of same, an...
|
WO/2018/004065A1 |
The present invention relates to an aryl ethane derivative, for inhibiting an estrogen-related receptor gamma (ERRγ) activity, a prodrug of same, a solvate of same, a stereoisomer of same or pharmaceutically acceptable salts of same, an...
|
WO/2017/162156A1 |
An iridinesulfonamide compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity, pharmaceutically-acceptable salts, solvates or hydrates thereof, a pharmaceutical composition, as well as use of the compound or the pharmaceuti...
|
WO/2017/104589A1 |
Provided is a method for producing a perfluoroalkylated compound at low cost, safely and with high efficiency. A method for producing a perfluoroalkylated compound, comprising reacting a bis(perfluoroalkanoyl)peroxide with a compound tha...
|
WO/2017/011418A1 |
The present invention provides a various organic reaction that utilize an α,β-unsaturated compound to produce aziridine compounds and dihydrofuran compounds. In particular, the present invention provides a method for producing an aziri...
|
WO/2015/142001A2 |
Disclosed are a compound having cardiotonic activity and a pharmaceutical composition containing the same, and the composition containing the compound, according to the present invention, is useful for preventing and treating heart failure.
|
WO/2015/120820A1 |
The present invention discloses a class of carboxylic acid derivatives and use thereof in preparation of prodrugs. The carboxylic acid derivatives have the general formula (I): R1 being H or an alkyl; X being H or F; Y being F or a fluor...
|
WO/2015/103505A2 |
A method for the direct stereospecific conversion of structurally diverse mono-, di-, tri- and tetra-substituted olefins to N-H, N-alkyl, N-cycloalkyl, or N-aralkyl aziridines using a hydroxylamine amination agent with transition metal c...
|
WO/2015/094710A1 |
The present disclosure is directed to a curable precursor of a pressure sensitive adhesive comprising: a) a (co)polymeric material comprising the reaction product of a (co)polymerizable material comprising a (meth)acrylate ester monomer;...
|
WO/2015/090084A1 |
The present invention relates to a catalyst for synthesizing ethylenimine as well as a preparation method and application thereof. The related catalyst comprises a carrier and metal ions loaded on the carrier; the carrier is a composite ...
|
WO/2015/090085A1 |
Disclosed are a joint production method and device for aziridine, piperazine and triethylenediamine. The method comprises: reaction 1, preparing piperazine and triethylenediamine by taking ethanol amine as a raw material under the existe...
|
WO/2015/083066A1 |
The present disclosure provides crystalline piperidine sulfamoyl intermediates of formula 8 and 9. The present disclosure also relates to an improved process for the preparation of cobicistat using compounds of formulae 8 and 9.
|
WO/2015/073622A1 |
Described herein are compositions and compounds having one or more aziridinyl groups, and methods of making the same. The compounds can also have one or more nitrogen atoms that each can be positively charged. The composition and compoun...
|
WO/2015/018676A1 |
The invention relates to a method for producing tris-aziridinomethane (I) by reacting aziridine with chloroform, characterized in that the molar ratio of aziridine to choroform is at most 3: 1.
|
WO/2014/124988A1 |
The invention relates to the use of amide derivatives of the formula (I) wherein X1, X2, X3, X4, Z1 and Y are as defined in the specification as herbicides. Furthermore, the present invention relates to certain novel substituted amide de...
|